blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3704156

EP3704156 - CD38-DIRECTED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  08.09.2023
Database last updated on 05.10.2024
FormerExamination is in progress
Status updated on  16.12.2021
FormerRequest for examination was made
Status updated on  07.08.2020
FormerThe international publication has been made
Status updated on  11.05.2019
Formerunknown
Status updated on  23.11.2018
Most recent event   Tooltip08.09.2023Application deemed to be withdrawnpublished on 11.10.2023  [2023/41]
Applicant(s)For all designated states
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, California 92121 / US
[2020/37]
Inventor(s)01 / ZHANG, Yanliang
10945 Corte Mejillones
San Diego California 92130 / US
02 / ZHOU, Heyue
15732 Potomac Ridge Road
San Diego California 92127 / US
03 / MA, Qianzhong
4955 Directors Place
San Diego California 92121 / US
 [2020/37]
Representative(s)Script Intellectual Property LLP
Suite J, Anchor House
School Close
Chandlers Ford
Eastleigh, Hampshire SO53 4DY / GB
[N/P]
Former [2020/37]Script IP Limited
Turnpike House
18 Bridge Street
Frome Somerset BA11 1BB / GB
Application number, filing date18801058.102.11.2018
[2020/37]
WO2018IB58642
Priority number, dateUS201762581466P03.11.2017         Original published format: US 201762581466 P
[2020/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019087151
Date:09.05.2019
Language:EN
[2019/19]
Type: A1 Application with search report 
No.:EP3704156
Date:09.09.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 09.05.2019 takes the place of the publication of the European patent application.
[2020/37]
Search report(s)International search report - published on:EP09.05.2019
ClassificationIPC:C07K16/28, A61K39/00
[2020/37]
CPC:
C07K16/2896 (EP,KR,US); A61K39/0011 (US); A61K39/4611 (EP,KR);
A61K39/4631 (EP,KR); A61K39/464426 (EP,KR); A61P35/00 (KR);
C07K14/7051 (US); C07K14/70517 (US); C07K14/70521 (US);
A61K2039/505 (EP,KR,US); A61K2039/5156 (US); A61K2039/5158 (US);
A61K2239/31 (EP,KR); A61K2239/38 (EP,KR); A61K2239/48 (EP,KR);
C07K2317/30 (KR); C07K2317/73 (EP,KR,US); C07K2319/00 (EP,KR,US);
C07K2319/03 (US); C07K2319/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/37]
TitleGerman:CD38-GERICHTETE CHIMÄRE ANTIGENREZEPTORKONSTRUKTE[2020/37]
English:CD38-DIRECTED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS[2020/37]
French:CONSTRUCTIONS DE RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE DIRIGÉ CONTRE CD38[2020/37]
Entry into regional phase28.05.2020National basic fee paid 
28.05.2020Designation fee(s) paid 
28.05.2020Examination fee paid 
Examination procedure28.05.2020Amendment by applicant (claims and/or description)
28.05.2020Examination requested  [2020/37]
28.05.2020Date on which the examining division has become responsible
15.12.2021Despatch of a communication from the examining division (Time limit: M04)
22.04.2022Reply to a communication from the examining division
22.07.2022Observations by third parties
03.11.2022Despatch of a communication from the examining division (Time limit: M06)
16.05.2023Application deemed to be withdrawn, date of legal effect  [2023/41]
07.06.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2023/41]
Fees paidRenewal fee
28.12.2020Renewal fee patent year 03
29.11.2021Renewal fee patent year 04
28.11.2022Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.11.202003   M06   Fee paid on   28.12.2020
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2015121454  (CELLECTIS [FR]) [I] 1-30 * example all *;
 [I]WO2017025323  (CELLECTIS [FR]) [I] 1-30 * figure all; example all *;
 [I]  - E. DRENT ET AL, "Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, IT, (20160208), vol. 101, no. 5, doi:10.3324/haematol.2015.137620, ISSN 0390-6078, pages 616 - 625, XP055460439 [I] 1-30 * figure all *

DOI:   http://dx.doi.org/10.3324/haematol.2015.137620
 [I]  - ESTHER DRENT, "CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20141201), vol. 124, no. 21, ISSN 0006-4971, page 4759, XP009187479 [I] 1-30 * the whole document *
 [I]  - Sorrento Therapeutics ET AL, "Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies", (20161201), URL: https://www.prnewswire.com/news-releases/sorrentos-tnk-therapeutics-provides-progress-update-for-its-anti-cd38-and-cd123-car-t-programs-for-treatment-of-hematological-malignancies-300371312.html, (20181204), XP055529817 [I] 1-30 * the whole document *
 [I]  - DJORDJE ATANACKOVIC ET AL, "Immunotherapies targeting CD38 in Multiple Myeloma", ONCOIMMUNOLOGY, (20160805), vol. 5, no. 11, doi:10.1080/2162402X.2016.1217374, page e1217374, XP055505109 [I] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1080/2162402X.2016.1217374
by applicantUS4946778
 US6696245
 US6846634
 WO2012031744
 WO2014055668
 US8802374
 WO2016012623
 US2016152723
 US2016297888
    - TANIGUCHI et al., Blood, (20070000), vol. 110, pages 2020 - 2023
    - LEISEGANG, M.; WILDE, S.; SPRANGER, S.; MILOSEVIC, S.; FRANKENBERGER, B.; UCKERT, W.; SCHENDEL, D. J., "MHC-restricted fratricide of human lymphocytes expressing surviving-specific transgenic T cell receptors", The Journal of Clinical Investigation, (20100000), vol. 120, doi:doi:10.1172/JCI43437, pages 3869 - 3877, XP055103910

DOI:   http://dx.doi.org/10.1172/JCI43437
    - SCHENDEL, D. J.; FRANKENBERGER, B., "Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity", Oncoimmunology, (20130000), vol. 2, page e22410
    - FERLAY et al., Int. J. Cancer, (20150000), vol. 136, no. 5, pages E359 - 386
    - KUMAR et al., Blood, (20080000), vol. 111, no. 5, pages 2516 - 2520
    - KHARFAN-DABAJA et al., J. Hematol. Oncol., (20130000), vol. 6, page 2
    - ESHAR et al., Proc. Nat'l. Acad. of Sci. USA, (19930000), vol. 90, no. 2, pages 720 - 724
    - GROSS et al., Proc. Nat'l. Acad. of Sci. USA, (19890000), vol. 86, no. 24, pages 10024 - 10028
    - HAYNES et al., The Journal of Immunology, (20010000), vol. 166, no. 1, pages 182 - 187
    - FINNEY et al., Journal of Immunology, (19980000), vol. 161, no. 6, pages 2791 - 2797
    - HOMBACH et al., Journal of Immunology, (20010000), vol. 167, no. 11, pages 6123 - 6131
    - MAHER et al., Nature Biotechnology, (20020000), vol. 20, no. 1, pages 70 - 77
    - EMTAGE et al., Clinical Cancer Research, (20080000), vol. 14, no. 24, pages 8112 - 8812
    - LO et al., Clinical Cancer Research, (20100000), vol. 16, no. 10, pages 2769 - 2780
    - GOEDDEL, Gene Expression Technology: Methods in Enzymology, Academic Press, (19900000), vol. 185
    - BARON et al., Nucleic Acids Res., (19950000), vol. 23, pages 3605 - 3606
    - GENTRY et al., Leuk. Res., (20040000), vol. 28, no. 3, pages 307 - 313
    - GLUZMAN et al., Cell, (19810000), vol. 23, page 175
    - RASMUSSEN et al., Cytotechnology, (19980000), vol. 28, page 31
    - URLAUB et al., Proc. Natl. Acad. Sci. USA, (19800000), vol. 77, pages 4216 - 4220
    - MCMAHAN et al., EMBO J., (19910000), vol. 10, page 2821
    - GROSS, Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 10024 - 10028
    - SAKEMURA, Cancer Immunology Research, (20160000), vol. 4, no. 8, pages 658 - 668
    - ESHHAR et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, no. 2, pages 720 - 724
    - MA et al., Cancer Chemother. Bio. I Response Modif., (20020000), vol. 20, pages 315 - 341
    - KORTT et al., Prot. Eng., (19970000), vol. 10, page 423
    - KORTT et al., Biomol. Eng., (20010000), vol. 18, pages 95 - 108
    - KRIANGKUM et al., Biomol. Eng., (20010000), vol. 18, pages 31 - 40
    - BIRD, Science, (19880000), vol. 242, page 423
    - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, page 5879
    - WARD et al., Nature, (19890000), vol. 334, page 544
    - DE GRAAF et al., Methods Mol. Biol., (20020000), vol. 178, pages 379 - 387
    - BAROSI et al., Ann. Hematol., (20120000), vol. 91, no. 6, pages 875 - 888
    - DEAGLIO et al., J. Immunol., (19980000), vol. 160, no. 1, pages 395 - 402
    - SANDOVAL-MONTES; SANTOS-ARGUMEDO, J. Leukocyte Biol., (20050000), vol. 77, no. 4, pages 513 - 521
    - MIHARA et al., J. Immunother., (20090000), vol. 32, no. 7, pages 737 - 743
    - MIHARA et al., Br. J. Haematol., vol. 151, no. 1, pages 37 - 46
    - BHATTACHARYYA et al., Blood Cancer J, (20120000), vol. 2, no. 6, page e75
    - DRENT et al., Haematologica, (20160000), vol. 101, no. 5, pages 616 - 625
    - DALTON et al., Cancer Research, (19860000), vol. 46, pages 5125 - 5130
    - GENTY et al., Leuk Res, (20040000), vol. 28, no. 3, pages 307 - 313
    - GREGORINI, TOMASETTI et al., Cell Biology International, (20060000), vol. 30, no. 9, pages 727 - 732
    - MA et al., The Prostate, (20040000), vol. 61, pages 12 - 25
    - MA et al., The Prostate, (20140000), vol. 74, no. 3, pages 286 - 296
other   - DRENT et al., "A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization", Molecular Therapy, (20170000), vol. 25, no. 8, doi:10.1016/j.ymthe.2017.04.024, pages 1946 - 1958, XP002792653

DOI:   http://dx.doi.org/10.1016/j.ymthe.2017.04.024
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.